Click here for slides on this topic


Dipeptidyl peptidase-4 (DPP-4) inhibitors

A class of oral antihyperglycemic agents that inhibit the activity of DPP-4. Also referred to as dipeptidyl peptidase-IV (DPP-IV) inhibitors.
The following content matched the glossary term: Dipeptidyl peptidase-4 (DPP-4) inhibitors

NDEI.org Expert Commentary Silvio E. Inzucchi MD on Type 2 Diabetes Treatment Recommendations

Top

EXPERT COMMENTARY New Silvio E. Inzucchi, MD, on Phentermine Plus Topiramate for Weight Loss in Type 2 Diabetes   Silvio E. Inzucchi, MD  Weight loss remains a great challenge for our patients, especially those with type 2 diabetes. While lifestyle

AACE 2015 guidelines Glycemic Control Algorithm

Top

AACE’s glycemic control algorithm outlines pharmacologic treatment options for diabetes from the 2015 AACE guidelines 

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Top

White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: Dipeptidyl peptidase-4 (DPP-4) inhibitors Slides Found: 11
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
DPP-4 Inhibitors: Dosage Adjustment by Degree of Renal Impairment
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI